A detailed history of Vanguard Group Inc transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Vanguard Group Inc holds 41,683,055 shares of ROIV stock, worth $499 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
41,683,055
Previous 8,191,824 408.84%
Holding current value
$499 Million
Previous $86.6 Million 455.54%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.17 - $12.5 $341 Million - $419 Million
33,491,231 Added 408.84%
41,683,055 $481 Million
Q2 2024

Aug 13, 2024

BUY
$10.36 - $11.74 $885,697 - $1 Million
85,492 Added 1.05%
8,191,824 $86.6 Million
Q1 2024

May 10, 2024

BUY
$9.87 - $11.8 $10.2 Million - $12.2 Million
1,030,681 Added 14.57%
8,106,332 $85.4 Million
Q4 2023

Feb 14, 2024

BUY
$8.38 - $11.58 $12.3 Million - $17.1 Million
1,473,085 Added 26.29%
7,075,651 $79.5 Million
Q3 2023

Nov 14, 2023

BUY
$9.76 - $13.19 $33.6 Million - $45.4 Million
3,440,374 Added 159.12%
5,602,566 $65.4 Million
Q2 2023

Aug 14, 2023

BUY
$7.09 - $10.08 $2.79 Million - $3.96 Million
393,350 Added 22.24%
2,162,192 $21.8 Million
Q1 2023

May 15, 2023

BUY
$6.92 - $9.98 $830,005 - $1.2 Million
119,943 Added 7.27%
1,768,842 $13.1 Million
Q4 2022

Feb 10, 2023

BUY
$3.36 - $7.99 $253,088 - $601,838
75,324 Added 4.79%
1,648,899 $13.2 Million
Q3 2022

Nov 14, 2022

BUY
$0.51 - $4.84 $29,185 - $276,973
57,226 Added 3.77%
1,573,575 $5.07 Million
Q2 2022

Aug 12, 2022

BUY
$2.81 - $4.84 $553,148 - $952,754
196,850 Added 14.92%
1,516,349 $6.17 Million
Q1 2022

May 13, 2022

BUY
$4.74 - $9.91 $757,390 - $1.58 Million
159,787 Added 13.78%
1,319,499 $6.52 Million
Q4 2021

Feb 14, 2022

BUY
$5.86 - $13.52 $6.8 Million - $15.7 Million
1,159,712 New
1,159,712 $11.7 Million

Others Institutions Holding ROIV

About Roivant Sciences Ltd.


  • Ticker ROIV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 704,382,976
  • Market Cap $8.43B
  • Description
  • Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...
More about ROIV
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.